Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Carmen Balaña Pilar Sánchez-Gómez Maria Martinez Garcia Gaspar Reynés |
| Publication date | October 1, 2017 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |